The age-old theory that imparted the status of "dead, (clonidine) have been available in the transdermal form, impermeable barrier devoid of biological activity" to skin they have reduced cardiovascular emergencies had already been challenged by the development of significantly. This article is dedicated to the review of pioneering transdermal products 1 . But a less than transdermal research in the area of cardiovascular agents impressive commercial growth in this sector had raised reported in various pharmaceutical journals. some doubts about the feasibility of this route as an efficient device of drug delivery. The journey of Transdermal delivery systems (TDDS) transdermal research had commenced with a lot of benefits: enthusiasm, as it heralded the promise of noninvasive Transdermal systems are ideally suited for diseases that cutaneous application 1 . The projected advantages were demand chronic treatment. Hypertension, a disease publicized so much that the target consumers were equally prevalent in the developed and the prepared to accept the products even if they were underdeveloped countries, demands chronic treatment. costlier alternatives to the conventional therapy. This An analysis shows that cardiovascular disease (CVD) was acceptability factor had encouraged researchers and responsible for the highest mortality rate, and mild industries alike to take up challenging projects in this hypertension may be the humble beginning for the fatal -risks and particular arena. For the last two decades, it remained an area of vital research interest, and data was generated for almost every available drug 2 .
The extensive work of last 25 years has generated around 10 marketed transdermal patches and a large number of patents. Surveys had been undertaken to assess the contribution of these products to medical expenditure and clinical benefits too. It was found that though only two antianginal (nitroglycerin and isosorbide dinitrate) agents and one antihypertensive agent *For correspondence E-mail: bijayadd@yahoo.co.in cardiovascular ailments 3 . Hypertensive patients need to be on prolonged medication, and sometimes lifelong therapy is advised. Hence noncompliance of the therapy, especially in cases where dosing frequency is high, is a major problem. Transdermal delivery is considered to be the ideal method which can bypass the difficulties of first pass metabolism, enable absolute elimination of GIT toxic effects, maintain the steady plasma level of drug for a prolonged period and deliver the drug at predetermined rate without the hazards of specialist care as is required in the intravenous infusion 4 . Since transdermal patches offer a better quality of life, they are more popular than the oral dosage forms [5] [6] . Sizeable number of antihypertensives undergo extensive first-pass metabolism, www.ijpsonline.com which too can be avoided by transdermal therapy. Hence cardiovascular agents of both therapeutic and prophylactic usage have been subjected to transdermal investigation.
So far, few investigations have been carried out with the primary objective to evaluate the efficacy and risk factors of TDDS patches in heart patients [7] [8] . However, a study using nicotine patch specifically conducted to evaluate the safety of TDDS on heart patients has showed no additional cardiovascular risks 9 . Nicotine is a ganglion stimulant, which increases the heart rate; so the safe the patches used to prevent cardiovascular disorders are of higher clinical benefit. Hence we would start the discussion with the analysis of existing cardiovascular patches.
Courtesy transdermal development, nitroglycerin, a drug that had lost its popularity in the 1960s, was reintroduced for clinical use 13 . Unsuitable for gastrointestinal administration owing to its low oral bioavailability (1%), its use was restricted to sublingual and topical form. Absorption of this drug from these forms was low and result indicates that patches or adjuvants used in the variable (26-34%), and inadequate understanding of the patches as such do not involve any additional risk for the pharmacology had raised doubts about its clinical heart patients. However, dose dumping or inadequate efficacy 13 . Until 1970, the only alternative for the release both could be a significant disadvantage for a sublingual therapy was an intravenous infusion, patch-type dosage form. Major tragedies had occurred occasionally used in the intensive care units on patients because of improper use of fentanyl patches, and FDA undergoing treatment for severe chest pain. In 1981, has cautioned health care providers against the overdose introduction of the transdermal patch opened up the from transdermal systems 10 . Fentanyl is a potent drug, possibilities of its prolonged and continuous use to which is marketed in TDDS form as a pain reliever. Since prevent the unwarranted attacks of angina 14 skin offers high resistance to the absorption of drugs, the patches contain much higher amount of the active Transderm-Nitro patches, one of the first two transdermal ingredient (approximately 20-25 times) than the amount systems to be marketed, owed their success to a intended to be absorbed. Fentanyl patches carry the favourable pharmacodynamic parameter of the drug. black box warning and are advised to be used with Effective at low plasma concentration (1.2-11 ng/ml), a utmost caution. Catapres-TTS, the only antihypertensive dose in the microgram ranges is sufficient to control the available as TDDS, comes in three dose levels (0.1 mg, angina 15 . Presently there are four manufacturers in the 0.2 mg and 0.3 mg), and the physicians are advised to market selling the drug in the transdermal form: (Deponit titrate the dosage according to the individual's therapeutic Schwarz/Lohmann, Nitrodisc-Searle, NitroDur-Key requirements. While substituting the patch for the oral Pharmaceuticals and Transderm Nitro-Ciba) 1 . On the antihypertensive therapy, a gradual reduction of the oral technological basis too, nitroglycerin delivery systems can dose is advised as the antihypertensive effect from the be classified into four categories. Transderm-Nitro is a patch might not commence until 2-3 d after initial polymer membrane permeation control system, whereas application. With initial therapy of Catapres-TTS, mild in Deponit the drug is dispersed in adhesive polymer sedation, tiredness and dryness of mouth is usual.
matrix. Nitrodisc carries the drug in micro reservoirs, and Catapres-TTS also caused lowering of heart and pulse NitroDur system uses nonadhesive polymers as the base 1 rate, and a lowering of heart rate below 56 beats must An evaluation of these patches have revealed that .
. be avoided for safety. The reports indicate that though the intensity of the side effects is low with the patches, they cannot altogether be avoided and should be used with caution
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The marketed patches:
Commercially available transdermal patches are limited in number, but this small group of marketed products represents many important classes: antianginal (nitroglycerin, isosorbide dinitrate), antihypertensive (clonidine), antiemetics (scopolamine), hormones (estrodiol, testosterone), opioids (fentanyl) and anticholinergic (nicotine) 12 . The statistics procured from market survey show that the sales of anaesthetic patches are high, but Transderm-Nitro is better than its two marketed counterparts as it resulted in the highest area under plasma concentration curve and the least coefficient of variation in a comparative study 16 . Yet another study says, though the drug penetrates from the Nitrodisc system at a greater rate, the products are clinically interchangeable 17 . Support for transdermal therapy has also come from another significant clinical study. Patients of unstable angina who could only be sustained by IV nitroglycerin in the intensive care unit responded to transdermal nitroglycerin, which maintained the antiischaemic effects initially achieved with IV nitroglycerin 18 . Though the utility of the transdermal nitroglycerin is yet to be established in the whole spectrum of coronary heart www.ijpsonline.com diseases, it has already improved the quality of life of the ambulant ischemic patients. Special benefits in terms of improvement in haemodynamic abnormalities, reduction in the infarct size and reduction of life-threatening arrhythmias have been noted amongst the users of the products. Finally, the American Heart Association has endorsed the utility of the transdermal form in acute myocardial infarction irrespective of the involvement of left ventricular failure 19 . The proven clinical efficacy and assured market has sustained the research interest on this drug. Work is going on to optimize transdermal therapy of nitroglycerin generates pulsed release that is controlled by the production of hydrogen gas activated by a magnetic switch. The trend shows that the development of technology rather than the system will be the focus of transdermal delivery of nitroglycerin in the upcoming years.
Antiischaemics:
The other organic nitrate that has been marketed already in the transdermal form is isosorbide dinitrate. As skin is preferentially permeable to the lipid molecule, the fully by improvising both on formulations as well as nitrated lipophilic polyols are acceptable to skin. Bioavailability of isosorbide dinitrate when administered by conventional routes varies significantly. The drug has Research trends: a short half-life (0.8±0.4 h), demanding frequent Since barrier properties of intact skin vary widely among administration, and the prescribed dosage regimen is 2.5 and within the species, reproducibility in drug flux is a 10 mg every 2 to 3 h. From transdermal route, a flux of major challenge for transdermal dosage forms. Permeation 4.01 mg/h is necessary to achieve the level of clinical enhancers are mainly used to overcome this high efficiency of maintenance therapy
24
. However, in 1984 a resistance and increase the flux to clinically beneficial Japanese company "Toa Eiyo" had launched frandol levels 20 . An experimental system reported by Varshney et tape in the market, containing the drug in adhesive al.
21 makes use of Aerosol-OT (AOT), an ionic moiety of polymer dispersion. The frandol tape, a once-daily the surfactant docusate sodium, to enhance the transdermal patch, had reduced the inconvenience of permeation of nitroglycerin. Here the drug is frequent administration and gained wider acceptance. In encapsulated in reservoirs with surfactants arranged in 1999, another group attempted to develop a membrane normal and reverse micellar pattern. The authors have controlled transdermal system of isosorbide dinitrate using shown that 5% weight of AOT in water, arranged in carbomer gel as the drug reservoir. Here ethylene vinyl normal micellar pattern, can increase the permeability of acetate copolymers and polyethylene membranes were nitroglycerin 12.3-fold 21 . Comparable enhancement and used as rate-controlling devices. The release rate slightly better skin compatibility were found in reverse achieved using the polyethylene rate controller mimicked micellar patterns where the AOT was contained in the commercial product and was close to the target flux isopropyl myristate.
and was thought to be promising for commercial development 24 . However, the drug is not free from Because of the rate-controlling effect of stratum corneum, cutaneous metabolism. It was found that while penetrating the attainment of much-desirable zero-order drug the skin layer, isosorbide dinitrate gets converted to delivery was relatively easy through skin, but it was not isosorbide-2-mononitrate and isosorbide-5-mononitrate, free of disadvantages. Prolonged exposure to a steady indicating a possibility of structural change during the techniques.
concentration of a drug could make the body immune to its beneficial therapeutic effects by inducing tolerance 22 . So attempts were made to develop systems that would release variable amount of drugs at different time intervals, and the technique of enhancer depletion was attempted.
Recently with the advent of iontophoresis, systems with active release control have become a reality. Systems combining electronic circuits and special formulation techniques (discontinuous distribution of nitroglycerin in the reservoir) have been developed to monitor the drug release during emergency or at the volition of the patient 23 . The drug reservoir with its discontinuous layers permeation 25 . Some workers have used the sophisticated electron beam irradiation technique to synthesize matrix system of the drug 26 . It was found that a particular irradiation dose of 50 kGy is successful in delivering the drug at a higher rate than the marketed product, opening the possibility of improved patch compared to the commercially available one 27 .
Verapamil, a phenyl alkyl derivative used in hypertension, angina and supraventricular arrhythmias, has drawn the attention of transdermal researchers 28, 29 . As the free base is more lipophilic than the hydrochloride salt, skin permeability studies are usually conducted in the free base form. Studies of in vitro permeation showed www.ijpsonline.com promising results 30 . In vivo studies conducted in rats using absorption promoter azone also reported significant enhancement in permeation for the drug 31 . Another in vivo study that delivered the drug from matrix system of Eudragit and HPMC to rabbits had reported successful maintenance of steady and adequate plasma levels up to 24 h of administration 32 . One study aimed at assessing the pharmacokinetic profile of transdermal verapamil using human males as subjects had reported that both steady state plasma concentration and area under the plasma concentration curve for total verapamil concentration (Catapres-TTS) has been evaluated for clinical efficacyalone and in combinations with diuretics 40 . Clonidine, an α 2 adrenergic agonist, is effective in low doses but was used with caution because of its centrally acting nature. Serious side effects like sedation and xerostomia along with dry nasal mucosa and parotid swelling occur in at least 50% of patients, leading to the discontinuation of therapy when administered orally 41 . However, transdermal patches were rated better in comparison to the conventional dosage forms. Studies involving large populations were carried out in which transdermal form were proportional to the surface area of the delivery was found to be better tolerated, requiring no system 33 . Amongst the other dihydropyridines of discontinuation of therapy 42 . One detailed study based on antianginal efficacy, amlodipine has been studied for the retrospective analysis of the Medicaid claims in two transdermal permeation. Systems have been formulated American states, Florida and South Carolina, had shown for this drug using penetration enhancers sodium lauryl that though the prescription expenditure of the patients sulphate and propylene glycol, etc. But in vitro studies using the patch was significantly higher, it saved them indicated a flux value inadequate for clinical use 34 .
from hospitalization and diagnostic costs and reduced the overall health expenditure. Nifedipine, a drug of proven efficacy in the treatment of angina and hypertension both, has been dealt with A mechanistic study performed on human epidermal caution. The drug suffers from the disadvantage of keratinocytes cell culture revealed that the transport of photosensitivity, and prolonged processing usually clonidine is affected by pH. The experiment indicated interferes with its stability 35 . Till the early '90s, nifedipine that clonidine transport beyond the epidermal layer was research was focused on the development of oral affected by tertiary amine transport system and could be sustained release dosage forms 36 . Recently some attempts inhibited by competition with other amines like tryptamine, have been undertaken to develop transdermal systems diphenhydramine, quinine and guanidine 43 . Clonidine is for this difficult drug, and studies have revealed widely used now in the transdermal form, and the interesting results. Though the measured physicochemical industries are in competition to evolve better systems. properties showed favourable permeation potentials, the Bupranolol, a drug with extensive first-pass metabolism drug showed very poor skin permeability. Wide ranges (90%), had generated interest from the early days of of penetration enhancers, like sodium lauryl sulphate, transdermal research. High expectations were generated propylene glycol, etc., have failed to improve the as pharmacodynamic studies carried out with adhesive permeability to an acceptable level 37 . The actual transdermal patches of the drug showed effectiveness permeation data obtained on this drug seems to defy all comparable to that of bupranolol infusions in rabbits 44 the empirical guidelines and shows no correlation The experimental patch applied to a wider area in human between the drug solubility and steady state flux 38 .
volunteers showed that bupranolol penetrated in sufficient .
Antihypertensives:
Another group of cardiovascular agents that had generated excitement amongst the transdermal scientists is antihypertensives, specifically the ß-adrenergic receptor antagonists. These drugs have multiple utilities and are administered in hypertension; ischaemic heart diseases, including certain types of arrhythmias. Since antihypertensives suffer from the disadvantage of extensive first-pass metabolism and variable bioavailability, they were considered ideal transdermal candidates 39 .
Clonidine was the first antihypertensive agent to be launched in the transdermal form. Since then the patch amounts to have pronounced pharmacological effects against isoprenaline-challenged tachycardia 45 . Recently a study using partially methylated β-cyclodextrin as enhancer had reported good permeation of the drug 46 . Later the same researchers have developed a reservoir type system for the drug, from which the permeation rate achieved was 4 to 5 times more than the desired flux 47 .
Amongst the other antihypertensives, propranolol, a drug with desirable hydrophilic-lipophilic balance, has created high expectations. Enormous data has been generated for this drug as it is also used as a model molecule for mechanistic studies and system development [48] [49] [50] [51] [52] . However, initial studies carried out to evaluate www.ijpsonline.com permeability showed that the drug induces inflammatory reactions 53 . A self-assembled pharmacogel using synthesized prodrugs propranolol palmitate hydrochloride and propranolol stearate hydrochloride was found to increase the enhancement rate and was also free of inflammatory reactions. The gel containing the lamellar liquid crystals could achieve high chemical potential and showed the promise of successful percutaneous delivery of the drug 54 .
Simultaneously work is going on to develop a suitable manner and is sufficient to cause effective permeation 62 . One of our studies had used the prodrug approach, where atenolol esters were prepared to increase its lipophilicity and permeation studies were carried out in isolated porcine skin; promising results were obtained with caproate ester 63 .
Metoprolol reduces the blood pressure by reduction of cardiac output via slowing of the heart rate and finds substantial use in antihypertensive therapy. The basic drug with a pK a value of 9.5 and moderately high delivery system for propranolol. Trials have been molecular weight has been investigated both by passive undertaken with various natural and artificial polymers to diffusion and iontophoresis 64, 65 . develop reservoirs and rate-controlling membranes. There are reports on the development of gel-type Significant enhancement of permeation (130-fold) was reservoirs using natural polymer chitosan. Rate-controlling observed in one study where the permeation enhancer membranes of varying permeability obtained by azone was used along with iontophoretic technique 66 . A controlled cross-linking with gluteraldehyde were also bioavailability study carried out on hairless rats had developed using propranolol as model drug 55 . Same shown much superior systemic bioavailability of the drug authors have developed systems using collagen from adhesive transdermal patches as compared to the membrane as a rate-controlling device and reported conventional oral forms 65 . Work has also been reported successful regulation of drug release 56 . However, there is on the development of transdermal metoprolol system in a recent claim that systems developed with commercially which a composite release pattern adequate to supply the available ucecryl polymer can deliver the drug most therapeutic need has been claimed by the researchers 67 Intrinsic permeability data was also generated for some new drugs nimodipine, nicardipine, etc., using various The ß-blocker timolol belongs to the category of animal skins [68] [69] . antihypertensives but is widely used for treatment of glaucoma 58 . Conventional systems carry the drug in the
CONCLUSIONS
form of maleate ester because it enhances the gastrointestinal solubility. However, skin permeation The advanced state of research and the plethora of studies conducted on this drug used the free base timolol, patent applications filed for transdermal systems clearly and systems developed with the free base form showed indicate the renewed interest of pharmaceutical industry the promise of maintaining an adequate zero-order in the transdermal field. To include the drugs of poor plasma profile 59 . In the recent past, timolol has been skin permeability into the transdermal arena, painstaking assessed for iontophoretic delivery too. As electrical efforts are being invested to obtain drug derivatives of resistance changes widely in the natural skin, favourable physicochemical properties.
. effectively 57 . iontophoretic studies usually use artificial membranes of various pore sizes. In such a study, timolol maleate showed high and adequate permeability through such a microporous membrane, which had resistance comparable to that of the skin 60 .
Atenolol, a hydrophilic drug, with a relatively high effective concentration was less investigated compared to other β-blockers. Limited data available on the permeation studies shows that permeation increases in presence of chemical enhancers 61 . Recent study had shown that a matrix system containing ethyl vinyl acetate and polyoxyethylene 2-oleyl ether as penetration enhancers releases the drug in a diffusion-controlled Simultaneously to combat the permeability problems associated with skin, a band of researchers have started exploring the sophisticated techniques of permeation enhancement. The use of electron beam radiation in the development of transdermal systems has opened up newer channels. There is hope that the drugs that have been written off as poor candidates would be developed into successful transdermal systems in the near future. ) .
